BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saketkoo LA, Scholand MB, Lammi MR, Russell AM. Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials. J Scleroderma Relat Disord 2020;5:48-60. [PMID: 32455167 DOI: 10.1177/2397198320904178] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Campochiaro C, Lazzaroni MG, Bruni C, Zanatta E, De Luca G, Matucci-Cerinic M. Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review. Ther Adv Musculoskelet Dis 2022;14:1759720X221116408. [PMID: 36051631 DOI: 10.1177/1759720X221116408] [Reference Citation Analysis]
2 Lafyatis R, Valenzi E. Assessment of disease outcome measures in systemic sclerosis. Nat Rev Rheumatol 2022. [PMID: 35859133 DOI: 10.1038/s41584-022-00803-6] [Reference Citation Analysis]
3 Saketkoo LA, Obi ON, Patterson KC, Russell AM. Ageing with Interstitial lung disease: preserving health and well being. Curr Opin Pulm Med 2022;28:321-36. [PMID: 35749798 DOI: 10.1097/MCP.0000000000000880] [Reference Citation Analysis]
4 Kreuter M, Del Galdo F, Miede C, Khanna D, Wuyts WA, Hummers LK, Alves M, Schoof N, Stock C, Allanore Y. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. Arthritis Res Ther 2022;24:19. [PMID: 35012623 DOI: 10.1186/s13075-021-02710-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Pettersson H, Alexanderson H, Poole JL, Varga J, Regardt M, Russell AM, Salam Y, Jensen K, Mansour J, Frech T, Feghali-Bostwick C, Varjú C, Baldwin N, Heenan M, Fligelstone K, Holmner M, Lammi MR, Scholand MB, Shapiro L, Volkmann ER, Saketkoo LA. Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS). Best Pract Res Clin Rheumatol 2021;:101695. [PMID: 34217607 DOI: 10.1016/j.berh.2021.101695] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
6 Allanore Y, Constans J, Godard D, de Pouvourville G, Bouee S, Jeanbat V, Teissier C, Le Lay K, Chollet J, Hachulla E. Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France. Journal of Scleroderma and Related Disorders 2022;7:49-56. [DOI: 10.1177/23971983211013979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ruaro B, Confalonieri M, Matucci-Cerinic M, Salton F, Confalonieri P, Santagiuliana M, Citton GM, Baratella E, Bruni C. The Treatment of Lung Involvement in Systemic Sclerosis. Pharmaceuticals (Basel) 2021;14:154. [PMID: 33668530 DOI: 10.3390/ph14020154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
8 Lescoat A, Murphy SL, Roofeh D, Pauling JD, Hughes M, Sandler R, Zimmermann F, Wessel R, Townsend W, Chung L, Denton CP, Merkel PA, Steen V, Allanore Y, Del Galdo F, Godard D, Cella D, Farrington S, Buch MH, Khanna D. Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. J Scleroderma Relat Disord 2021;6:66-76. [PMID: 34316516 DOI: 10.1177/2397198320961967] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]